gefitinib has been researched along with folic acid in 11 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (folic acid) | Trials (folic acid) | Recent Studies (post-2010) (folic acid) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 30,001 | 1,945 | 10,195 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Calhau, C; Giovannetti, E; Jansen, G; Kathmann, I; Lemos, C; Peters, GJ | 1 |
| Bayliss, G; He, S; Liu, N; Zhuang, S | 1 |
| Cui, W; Feng, B; Li, H; Liu, L; Liu, M; Shi, Y; Su, C; Su, R; Zhao, L | 1 |
| Chen, X; Gotoh, N; Horike, SI; Igarashi, K; Kato, K; Kita, K; Kohno, S; Meguro-Horike, M; Mukaida, N; Murayama, T; Nakata, A; Nishi, K; Nishimura, T; Saitoh, K; Sasaki, S; Soga, T; Takahashi, C; Tojo, A; Yano, S | 1 |
| Arya, M; Kaithwas, G; Kanoujia, J; Parashar, P; Saraf, SA; Singh, M; Tripathi, CB; Yadav, A | 1 |
| Li, X; Liu, Z; Wang, J; Xu, Y; Yang, Y; Zhang, Y; Zhao, Z | 1 |
| Chen, J; Huang, L; Li, X; Lin, J; Tu, Y; Zheng, R | 1 |
1 review(s) available for gefitinib and folic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for gefitinib and folic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Folic Acid; Gefitinib; Genotype; Humans; Neoplasm Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
EGFR activity is required for renal tubular cell dedifferentiation and proliferation in a murine model of folic acid-induced acute kidney injury.
Topics: Acute Kidney Injury; Animals; Apoptosis; Cell Dedifferentiation; Cell Proliferation; Creatinine; ErbB Receptors; Folic Acid; Gefitinib; Kidney Tubules; Mice; Mice, Inbred C57BL; PAX2 Transcription Factor; Phosphatidylinositol 3-Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2013 |
Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Autophagy; beta-Cyclodextrins; Cell Survival; Drug Delivery Systems; Folate Receptors, GPI-Anchored; Folic Acid; Gefitinib; HeLa Cells; Humans; Molecular Targeted Therapy; Nanoparticles; Quinazolines; Serum Albumin, Bovine; Spectroscopy, Fourier Transform Infrared | 2014 |
Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
Topics: Aminohydrolases; Aminoimidazole Carboxamide; beta Catenin; Carcinogenesis; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Folic Acid; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Metabolic Networks and Pathways; Methylenetetrahydrofolate Dehydrogenase (NADP); Mitochondria; Multifunctional Enzymes; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Purines; Ribonucleotides | 2019 |
A synergistic approach for management of lung carcinoma through folic acid functionalized co-therapy of capsaicin and gefitinib nanoparticles: Enhanced apoptosis and metalloproteinase-9 down-regulation.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capsaicin; Cell Survival; Down-Regulation; Drug Delivery Systems; Drug Liberation; Female; Folic Acid; Gefitinib; Humans; Lung Neoplasms; Male; Matrix Metalloproteinase 9; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols; Rats, Wistar; Urethane | 2019 |
Novel β-1,3-d-glucan porous microcapsule enveloped folate-functionalized liposomes as a Trojan horse for facilitated oral tumor-targeted co-delivery of chemotherapeutic drugs and quantum dots.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Transport; Cell Survival; Chitosan; Drug Compounding; Drug Liberation; Drug Synergism; Fluorescent Dyes; Folic Acid; Gefitinib; Humans; Liposomes; Male; Mice; Mice, Nude; Mouth Neoplasms; Porosity; Proteoglycans; Quantum Dots; Rats, Sprague-Dawley; Tissue Distribution; Zinc Oxide | 2020 |
Folic acid-mediated MSNs@Ag@Geb multifunctional nanocomposite heterogeneous platform for combined therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxorubicin; Folic Acid; Gefitinib; Humans; Lung Neoplasms; Manganese Compounds; Metal Nanoparticles; Nanocomposites; Nanoparticles; Oxides; Silicon Dioxide; Silver | 2022 |